High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00457418
Recruitment Status : Completed
First Posted : April 6, 2007
Results First Posted : July 31, 2013
Last Update Posted : June 7, 2017
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
The purpose of this study is to establish the pharmacokinetics of PEG-Intron, administered at a dose of 6 μg/kg/week for 8 weeks (induction treatment), followed by a dose of 3 μg/kg/week for up to 252 weeks (maintenance treatment), in patients with high risk melanoma.

Condition or disease Intervention/treatment Phase
Melanoma Drug: PEG-Intron Phase 1

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 32 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Pharmacokinetic Study of PEG-Intron, Administered Weekly in Subjects With High-Risk Melanoma
Actual Study Start Date : February 20, 2007
Actual Primary Completion Date : May 27, 2008
Actual Study Completion Date : July 11, 2012

Arm Intervention/treatment
Experimental: PEG-Intron

6 ug/kg/week, SC (first 8 weeks)

3 ug/kg/week, SC (252 weeks [weeks 9-260], maintenance)

Drug: PEG-Intron
Other Names:
  • SCH 054031
  • peginterferon alfa-2b

Primary Outcome Measures :
  1. Area Under the Curve (AUC) of PEG-Intron at 12 Weeks [ Time Frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks ]
    AUC was defined as the actual body exposure to drug after administration of a dose of the drug.

  2. Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks [ Time Frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks ]
    Cmax was defined as observed maximum plasma concentration.

  3. Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks [ Time Frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks ]
    Cavg was defined as average plasma concentration.

  4. Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks [ Time Frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks ]
    Cmin was defined as observed minimum plasma concentration.

  5. Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks [ Time Frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks ]
    Tmax was defined as time of maximum plasma concentration.

  6. Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks [ Time Frame: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks ]
    CL/F was defined apparent clearance - the volume of plasma in the vascular compartment cleared of drug per unit of time and per kilogram of body weight by the processes of metabolism and excretion.

Secondary Outcome Measures :
  1. Number of Participants Who Experienced an Adverse Event (AE) [ Time Frame: Entire study duration (up to 5 years) ]
    An adverse event (AE) was defined as any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, whether or not considered related to the use of that product.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subjects at least 18 years of age, of either sex, and of any race.
  • Cytologically or histologically-confirmed melanoma, arising from a cutaneous or unknown site of origin, at Stages IIB, IIC, IIIA, IIIB, IIIC according to the American Joint Committee on Cancer (AJCC) 2001 guidelines.
  • Adequate hepatic, renal and bone marrow function within 4 weeks prior to initiation of study treatment.
  • Subjects presenting with synchronous primary and regional melanoma must have had adequate surgical margins surrounding the primary lesion.
  • Full lymphadenectomy must be performed within 90 days prior to initiation of study treatment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Give informed consent according to International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and national/local policy.
  • Be able to adhere to dose and visit schedules.
  • Female subjects of childbearing potential must be using a medically accepted method of birth control prior to Screening and agree to continue its use during the study or be surgically sterilized.
  • Female subjects of childbearing potential must have a negative serum pregnancy test at Screening.

Exclusion Criteria:

  • Female subjects who are pregnant, intend to become pregnant, or are breastfeeding.
  • Previous treatment with interferon alpha, chemotherapy or immunotherapy for melanoma.
  • Ocular melanoma, or melanoma of the mucous membranes.
  • Evidence of distant or non-regional lymph node metastases.
  • In-transit melanoma, even if the lesion has been resected.
  • Disease that cannot be completely surgically resected.
  • Lack of recovery from recent surgery.
  • Prior malignancy within the past 5 years, except surgically cured squamous cell carcinoma of the skin, successfully resected early stage cutaneous melanoma, or cervical carcinoma in situ.
  • Severe cardiovascular disease.
  • Thyroid dysfunction not responsive to therapy.
  • Uncontrolled diabetes mellitus (in the opinion of the investigator).
  • Active autoimmune disease.
  • Active and/or uncontrolled infection.
  • History of seropositivity for human immunodeficiency virus (HIV).
  • Pre-existing psychiatric condition.
  • Clinical diagnosis of substance abuse of one or more of the following drugs within the following timeframes (excluding time spent in detoxification, hospitalization or incarceration):

    • Alcohol, intravenous drug use, inhalational, psychotropics, narcotics, cocaine, prescription or over-the-counter drugs: within 1 year of the Screening visit.
    • Methadone, buprenorphine hydrochloride (HCl), and/or butorphanol tartrate: within 1 year of Screening visit, unless subject has drug screen negative for other (non-narcotic) drugs documented in the past year and repeated negative within 2 months of Screening visit.
    • Multi-drug abuse (2 or more substances in 16a and 16b): within 3 years of Screening visit.
    • Marijuana:

      • If historic use is deemed excessive by the principal investigator (or medically qualified individual), or is interfering with the subject's life, then the subject is not eligible and should not be screened.
      • If marijuana use is not deemed excessive by principal investigator and does not interfere with life, subject must discontinue any current use of marijuana prior to entry into study.
  • Medical condition requiring chronic systemic corticosteroids.
  • Known allergy to the drug substance or any of the excipients in the PEG-Intron formulation.
  • Any situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
  • Use of any investigational drugs within 30 days of study entry.
  • Participation in other clinical studies of investigational treatments.

Publications of Results:
Responsible Party: Merck Sharp & Dohme Corp. Identifier: NCT00457418     History of Changes
Other Study ID Numbers: P04831
First Posted: April 6, 2007    Key Record Dates
Results First Posted: July 31, 2013
Last Update Posted: June 7, 2017
Last Verified: May 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Additional relevant MeSH terms:
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Peginterferon alfa-2b
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs